Craig Ritchie

List of Publications by Year
in descending order

54 papers	1,953 citations	279798 23 h-index	276875 41 g-index
65 all docs	65 docs citations	65 times ranked	3144 citing authors

#	Article	IF	Citations
1	Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project. Lancet Psychiatry,the, 2016, 3, 179-186.	7.4	171
2	Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study). Trials, 2019, 20, 191.	1.6	127
3	Metaanalysis of Randomized Trials of the Efficacy and Safety of Donepezil, Galantamine, and Rivastigmine for the Treatment of Alzheimer Disease. American Journal of Geriatric Psychiatry, 2004, 12, 358-369.	1.2	114
4	Measuring multimorbidity beyond counting diseases: systematic review of community and population studies and guide to index choice. BMJ, The, 2020, 368, m160.	6.0	103
5	The PREVENT study: a prospective cohort study to identify mid-life biomarkers of late-onset Alzheimer's disease. BMJ Open, 2012, 2, e001893.	1.9	93
6	Recommended cognitive outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of Alzheimer's Dementia project. Alzheimer's and Dementia, 2017, 13, 186-195.	0.8	85
7	Is late‐onset Alzheimer's disease really a disease of midlife?. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2015, 1, 122-130.	3.7	82
8	The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. International Journal of Geriatric Psychiatry, 2003, 18, 432-440.	2.7	79
9	Dementia trials and dementia tribulations: methodological and analytical challenges in dementia research. Alzheimer's Research and Therapy, 2015, 7, 31.	6.2	77
10	European Prevention of Alzheimer's Dementia Longitudinal Cohort Study (EPAD LCS): study protocol. BMJ Open, 2018, 8, e021017.	1.9	72
11	Metal-protein attenuating compounds and Alzheimer's disease. Expert Opinion on Investigational Drugs, 2004, 13, 1585-1592.	4.1	60
12	The midlife cognitive profiles of adults at high risk of late‐onset Alzheimer's disease: The PREVENT study. Alzheimer's and Dementia, 2017, 13, 1089-1097.	0.8	57
13	Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial. Lancet Psychiatry,the, 2018, 5, 553-563.	7.4	53
14	The Clinical Picture of Alzheimer's Disease in the Decade Before Diagnosis. Journal of Clinical Psychiatry, 2016, 77, e305-e311.	2.2	50
15	Structural neuroimaging in preclinical dementia: From microstructural deficits and grey matter atrophy to macroscale connectomic changes. Ageing Research Reviews, 2017, 35, 250-264.	10.9	48
16	Secondary prevention of Alzheimer's dementia: neuroimaging contributions. Alzheimer's Research and Therapy, 2018, 10, 112.	6.2	46
17	Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. Alzheimer's and Dementia, 2021, 17, 1189-1204.	0.8	44
18	Genome and epigenome wide studies of neurological protein biomarkers in the Lothian Birth Cohort 1936. Nature Communications, 2019, 10, 3160.	12.8	42

#	Article	IF	Citations
19	Functional neuroimaging findings in healthy middle-aged adults at risk of Alzheimer's disease. Ageing Research Reviews, 2017, 36, 88-104.	10.9	38
20	AMYPAD Diagnostic and Patient Management Study: Rationale and design. Alzheimer's and Dementia, 2019, 15, 388-399.	0.8	37
21	Developing an Explainable Machine Learning-Based Personalised Dementia Risk Prediction Model: A Transfer Learning Approach With Ensemble Learning Algorithms. Frontiers in Big Data, 2021, 4, 613047.	2.9	31
22	THE EUROPEAN PREVENTION OF ALZHEIMER'S DEMENTIA (EPAD) LONGITUDINAL COHORT STUDY: BASELINE DATA RELEASE V500.0. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-7.	2.7	31
23	A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration. International Journal of Geriatric Psychiatry, 2006, 21, 171-179.	2.7	30
24	Multi-method genome- and epigenome-wide studies of inflammatory protein levels in healthy older adults. Genome Medicine, 2020, 12, 60.	8.2	30
25	Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. Alzheimer's and Dementia, 2020, 16, 750-758.	0.8	29
26	The PREVENT research programme – A novel research programme to identify and manage midlife risk for dementia: the conceptual framework. International Review of Psychiatry, 2013, 25, 748-754.	2.8	26
27	Patient or client? The opinions of people attending a psychiatric clinic. Psychiatric Bulletin, 2000, 24, 447-450.	0.3	23
28	European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials. Alzheimer's and Dementia, 2018, 14, 837-842.	0.8	20
29	Souvenaid®: A new approach to management of early Alzheimer's disease. Journal of Nutrition, Health and Aging, 2014, 18, 291-299.	3.3	19
30	Predictors of adherence to atypical antipsychotics (risperidone or olanzapine) in older patients with schizophrenia: an open study of 3½ years duration. International Journal of Geriatric Psychiatry, 2010, 25, 411-418.	2.7	18
31	Protocol for a conversation-based analysis study: PREVENT-ED investigates dialogue features that may help predict dementia onset in later life. BMJ Open, 2019, 9, e026254.	1.9	18
32	Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's disease. BMJ Open, 2019, 9, e024498.	1.9	18
33	Resting-state brain connectivity in healthy young and middle-aged adults at risk of progressive Alzheimer's disease. Neuroscience and Biobehavioral Reviews, 2021, 129, 142-153.	6.1	18
34	Boosting translational research on Alzheimer's disease in Europe: The Innovative Medicine Initiative AD research platform. Alzheimer's and Dementia, 2015, 11, 1121-1122.	0.8	15
35	Cerebral small vessel disease in middle age and genetic predisposition to late-onset Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 253-258.	0.8	14
36	Inherited risk of dementia and the progression of cerebral small vessel disease and inflammatory markers in cognitively healthy midlife adults: the PREVENT-Dementia study. Neurobiology of Aging, 2021, 98, 124-133.	3.1	13

#	Article	IF	Citations
37	Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings. Alzheimer's Research and Therapy, 2020, 12, 8.	6.2	12
38	Proximity to dementia onset and multi-modal neuroimaging changes: The prevent-dementia study. NeuroImage, 2021, 229, 117749.	4.2	10
39	Minocycline 200‰mg or 400‰mg versus placebo for mild Alzheimer's disease: the MADE Phase II, three-arm RCT. Efficacy and Mechanism Evaluation, 2020, 7, 1-62.	0.7	10
40	I think, therefore I forget â€" using experimental simulation of dementia to understand functional cognitive disorders. CNS Spectrums, 2020, 25, 511-518.	1.2	9
41	NuBrain: UK consortium for optimal nutrition for healthy brain ageing. Nutrition Bulletin, 2020, 45, 223-229.	1.8	9
42	The Open-Access European Prevention of Alzheimer's Dementia (EPAD) MRI dataset and processing workflow. NeuroImage: Clinical, 2022, 35, 103106.	2.7	9
43	Cognitive Functions as Predictors of Alzheimer's Disease Biomarker Status in the European Prevention of Alzheimer's Dementia Cohort. Journal of Alzheimer's Disease, 2020, 74, 1203-1210.	2.6	7
44	Remote data collection speech analysis and prediction of the identification of Alzheimer's disease biomarkers in people at risk for Alzheimer's disease dementia: the Speech on the Phone Assessment (SPeAk) prospective observational study protocol. BMJ Open, 2022, 12, e052250.	1.9	7
45	Involving research participants in a pan-European research initiative: the EPAD participant panel experience. Research Involvement and Engagement, 2020, 6, 62.	2.9	6
46	Impact of cerebral blood flow and amyloid load on SUVR bias. EJNMMI Research, 2022, 12, 29.	2.5	6
47	Associations Between Multimorbidity and Cerebrospinal Fluid Amyloid: A Cross-Sectional Analysis of the European Prevention of Alzheimer's Dementia (EPAD) V500.0 Cohort. Journal of Alzheimer's Disease, 2019, 71, 703-711.	2.6	5
48	Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCT. Health Technology Assessment, 2018, 22, 1-62.	2.8	5
49	The association between personality disorder and an act of deliberate self harm in the older person. International Psychogeriatrics, 2011, 23, 299-307.	1.0	4
50	Associations between cerebrospinal fluid markers and cognition in ageing and dementia: A systematic review. European Journal of Neuroscience, 2022, 56, 5650-5713.	2.6	4
51	Atlas of Psychiatric Pharmacotherapy By SHILOH, NUTT AND WEIZMAN Martin Dunitz, London, U.K., 2000, reprinted 2002, U.K. Â£32.50.Paperback, pp. 235, ISBN 1 853 179 345. International Psychogeriatrics, 2005, 17, 139-140.	1.0	2
52	The European Prevention of Alzheimer's Disease Program: A Publicâ€"Private Partnership to Facilitate the Secondary Prevention of Alzheimer's Disease Dementia. , 2022, , 190-206.		1
53	Management of self-harm in older people. Psychiatric Bulletin, 2009, 33, 423-425.	0.3	0
54	Better together for better dementia research and care. Lancet Psychiatry,the, 2016, 3, 503-504.	7.4	0